








# LEO Pharma pipeline overview

## 2022 Q4

Project*	Description	Partners	Pre-clinical	Phase 1	Phase 2	Phase 3	Registration
<b>Delgocitinib</b> LP0133	A topical pan-JAK inhibitor under development for chronic hand eczema.						
<b>Delgocitinib</b> LP0133	A topical pan-JAK inhibitor under development for frontal fibrosing alopecia.						
<b>Anti IgE*B-cell</b> LP0201	A monoclonal antibody under development for atopic dermatitis.						
<b>Anti IgE*B-cell</b> LP0201	A monoclonal antibody under development for allergic asthma.						
<b>Anti IL-22R</b> LP0145	An anti-inflammatory monoclonal antibody under development for atopic dermatitis.						
<b>H4R antagonist</b> LP0190	A systemic anti-pruritic and anti-inflammatory H4 receptor antagonist under development for atopic dermatitis.						
<b>H4R antagonist</b> LP0190	A systemic anti-pruritic and anti-inflammatory H4 receptor antagonist under development for cholinergic urticaria.						
<b>IL-17A PPI</b> LP0200	An IL-17 small-molecule modulator under development for psoriasis.						



\*Project compounds in our pipeline are investigational only and have not been approved by any regulatory authority.

